



Center for Vaccine Ethics & Policy (CVEP)
Vaccines and Global Health: The Week in Review
18 July 2026 :: Issue 854

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

.....
.....

Global childhood immunization coverage inches forward despite conflict and hesitancy – UNICEF, WHO

Zero-dose children fell by nearly 750 000 in the past year, but drop-out numbers high and stagnant, increasing risk of disease outbreaks

15 July 2026 *Joint News Release – WHO-UNICEF*

In 2025, 90% of infants globally – or nearly 116 million – received at least one dose of a diphtheria, tetanus and pertussis (DTP) vaccine, and 85% – or 110 million – completed the full three-dose series, according to the annual WHO-UNICEF Estimates of National Immunization Coverage (WUENIC) released today.

While both indicators rose by one percentage point from the previous year, global coverage remains one point below 2019 levels – hovering within the same narrow range since 2009.

According to the data, **an estimated 13.5 million “zero-dose” children did not receive a single vaccine in their first year during 2025. While these represent nearly 750 000 fewer children than the previous year,** progress is offset by a rising number of children who start the schedule and do not complete it. Most of these children live in countries where national immunization programmes receive support from Gavi, the Vaccine Alliance.

Globally, 7.3 million infants are estimated to have received their first DTP dose but dropped out before receiving their first measles dose. This drop-out rate contributed to stalled measles coverage with 84% of children receiving the first measles dose (MCV1) and 77% receiving the second dose (MCV2). Both figures fall far short of the 95% threshold required to prevent outbreaks of this highly contagious virus. Consequently, 57 countries reported large or disruptive measles outbreaks in 2025.

“Governments and health workers have helped global vaccination rates bounce back after dropping significantly during the COVID-19 pandemic,” said **UNICEF Executive Director Catherine Russell**. “But millions of vulnerable children are still being left unprotected due to conflict, displacement, and poverty. We must reach every child, and we must rebuild trust where it is fraying. No child should suffer from a disease that a simple vaccine can prevent.”

Data from 195 countries show that 100 countries have maintained at least 90% coverage with three doses of DTP vaccine since 2019, with little progress in expanding this group. Of the countries below 90% coverage in 2019, 30 improved their rates over the past six years, but 65 countries are stagnating or falling behind, including 13 fragile, conflict-affected or vulnerable countries (FCV).

Compared to their 2019 baselines, the Americas and South-East Asia have fully recovered and improved their performance, with the latter now the highest performing region. While Africa, the Eastern Mediterranean, and Europe regions saw gains last year, their coverage remains below pre-COVID-19 pandemic levels. By contrast, the Western Pacific experienced a decline, leaving it the region furthest below its 2019 baseline.

Behind these global and regional averages are persistent threats that are driving variability and volatility in country-level vaccination coverage.

More than half of all zero-dose children live in FCV settings, even though they account for only about a third of the world's child population. In these settings, immunization programmes are often strained by political upheaval, insecurity, or chronic underfunding. For example, in a single year, Syria lost 6 percentage points on DTP1 coverage and 12 points on MCV1. However, Sudan recorded the largest single-country gain globally last year, increasing DTP1 coverage by 35 percentage points and lifting MCV1 coverage by 22 points, demonstrating what is possible when access to services improves even amid ongoing conflict.

In middle- and high-income countries, even where vaccines are fully accessible, coverage is slipping amid shifting political commitment, structural challenges or rising hesitancy. For example, South Africa's DTP1 coverage has fallen 20 percentage points since 2019 and continued to decline in 2025. After the largest increase in MCV1 coverage in the region in 2024, Bosnia and Herzegovina saw a 23-point drop in the past year.

"Every child, whether born into wealth or poverty, peace or conflict, deserves the lifegiving protection that vaccines provide. Immunization is one of the most cost-effective, most equitable, and most reliable interventions for protecting children's health and well-being," said **Dr Tedros Adhanom Ghebreyesus, WHO Director-General**. "Our greatest security begins with ensuring that everyone, wherever they may live, is protected from deadly diseases that vaccines have the power to prevent."

Over the past 25 years, sustained investments from governments and partners, commitments from communities, strengthened programmes, and broad public trust have reduced the annual number of zero-dose children by 40%. For example, in countries supported by Gavi, children today are protected against more diseases than ever before, with 74% average coverage today across a full course of WHO-recommended vaccines.

"The historic levels of immunization that we are seeing across lower income countries shows what can be achieved when all stakeholders work together towards a shared objective," said **Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance**. "As Gavi heads into a new five-year period, our great challenge now will be to maintain this momentum in the face of funding constraints, geopolitical uncertainty, and increasing outbreaks – while working harder to reach those children that still do not have access to immunization."

However, the foundations that enabled progress are now under significant strain. The full impact of cuts to international health financing announced over the past two years is not yet reflected in these estimates, but the data systems needed to track that impact and protect against backsliding are themselves showing strain.

According to the data, only 18 national immunization surveys were undertaken and submitted this round, down from 50 in 2024 and an average of 33 per year between 2015 and 2019. Weakening investments in the data systems needed to find and reach children who are missing out on vaccines will lead to outbreaks and deaths that could have been prevented, warn the agencies.

WHO and UNICEF are working with Gavi, the Vaccine Alliance and other partners to deliver the global Immunization Agenda 2030 (IA2030) goal to ensure vaccines reach everyone, everywhere, at every age, yet the world is further off track to reach the global target of reducing zero-dose children.

To make this sharp course correction and bridge the critical gap, WHO and UNICEF call on governments and relevant partners to:

- strengthen immunization in conflict and fragile settings to reach and retain children;
- counter false and misleading health information and fully support vaccine uptake acceleration;
- increase and sustain domestic and global funding for immunization programmes and partnerships, including Gavi; and
- invest in stronger data and disease surveillance systems to drive and guide high-impact immunization programme strengthening efforts.

.....

Immunization coverage

WHO 15 July 2026

Key facts

:: Globally in 2025, there were 13.5 million children missing out on any vaccination – so-called zero-dose children.

:: Coverage of a third dose of vaccine protecting against diphtheria, tetanus, and pertussis (DTP3) was 85% in 2025.

:: The proportion of children receiving a first dose of measles vaccine was 84% in 2025.

:: Global coverage for the first dose of HPV vaccine in girls was 33% in 2025.

:: Coverage of yellow fever vaccine in the countries at risk of it is 53%, well below the recommended 80%.

Overview

While immunization is one of the most successful public health interventions, coverage has held steady since 2024, but data highlight a troubling trajectory in progress toward key targets of the global Immunization Agenda 2030 (IA2030).

During 2025, about 85% of infants worldwide (110 million) received 3 doses of diphtheria-tetanus-pertussis (DTP3) vaccine, protecting them against infectious diseases that can cause serious illness and disability or be fatal. However, these global figures hide significant disparity among countries of different income strata, with low-income countries lagging behind.

Measles, because of its high transmissibility, acts as an early warning system, quickly exposing immunity gaps in the population. Still, nearly 21 million children missed their routine first dose of measles, far from the 2019 level of 19 million.

Global immunization coverage 2025

A summary of global vaccination coverage in 2025 follows.

Haemophilus influenzae type b (Hib) causes meningitis and pneumonia. The Hib vaccine had been introduced in 193 Member States by the end of 2025. Global coverage with 3 doses of Hib vaccine is estimated at 78%. There is great variation between regions. The WHO South-East Asia Region is estimated to have 94% coverage, while it is only 45% in the WHO Western Pacific Region.

Hepatitis B is a viral infection that attacks the liver. Hepatitis B vaccine for infants had been introduced nationwide in 190 Member States by the end of 2025. Global coverage with 3 doses of hepatitis B vaccine is estimated at 84%. In addition, 119 Member States introduced 1 dose of hepatitis B vaccine to newborns within the first 24 hours of life. Global coverage is 43% and is as high as 77% in the WHO Western Pacific Region, while it is estimated at only 11% in the WHO African Region.

Human papillomavirus (HPV) is the most common viral infection affecting the reproductive tract and can cause cervical cancer in women, other types of cancer, and genital warts in both men and women. The HPV vaccine was provided through national immunization programmes and services in 162 countries in 2025, including new introductions in 15 countries. By end 2025, 93 countries used a 1-

dose schedule, and globally more than 85% of girls aged 9–14 years vaccinated that year were on a single dose schedule.

Global coverage with the first dose of HPV vaccine among girls is now estimated at 33%. While still far from the 90% target by 2030, this represents a substantial increase from 17% coverage in 2019. The smaller increase in global coverage since last year was a result of new introductions and programme scale-up in several large countries, but this increase was offset by reductions in performance in some large countries.

Malaria is a life-threatening disease caused by parasites transmitted to people through the bites of infected anopheline mosquitoes. It remains one of the leading causes of death among children in sub-Saharan Africa. The Malaria Vaccine Implementation Programme (MVIP), coordinated by WHO and conducted in Ghana, Kenya and Malawi from 2019 to 2023 demonstrated high public impact with a vaccine-attributable 13% reduction in all-cause mortality among children age-eligible for vaccination and substantial reduction in hospitalizations for severe malaria. Since 2024, malaria vaccines have been further introduced in national immunization schedules and scaled-up across Africa as part of integrated malaria control activities. Twenty-five countries in Africa have introduced malaria vaccines at national or subnational level.

Measles is a highly contagious disease caused by a virus, which usually results in a high fever and rash, and can lead to blindness, encephalitis or death. By the end of 2025, 84% of children had received 1 dose of measles-containing vaccine by their second birthday, and 77% of children received 2 doses of measles vaccine. By the end of 2025, 192 Member States had included a second dose of measles vaccine in their national immunization schedules.

Bacterial meningitis is an often-deadly infection which also leaves 1 in 5 individuals with long-term devastating sequelae after the acute phase. Before MenAfriVac introduction in 2010, meningococcus serogroup A (NmA) caused 80% of meningitis epidemics in the African meningitis belt. By end 2025, 24 of 26 countries in the belt conducted preventive campaigns, and 15 introduced MenAfriVac in their routine immunization programme, reaching more than 400 million people. In 2025, coverage is at 61% in countries using MenAfriVac in routine immunization programmes (15 countries) and 30% overall in the 26 countries. No case of NmA meningitis has been confirmed in the belt since 2017. A gradual switch to a new pentavalent meningococcal ACWYX conjugate vaccine starting in 2025 will pave the way to make the meningitis belt history.

Mumps is a highly contagious virus that causes painful swelling at the side of the face under the ears (the parotid glands), fever, headache and muscle aches. It can lead to viral meningitis. Mumps vaccine had been introduced nationwide in 124 Member States by the end of 2025.

Pneumococcal diseases include pneumonia, meningitis and febrile bacteraemia, as well as otitis media, sinusitis and bronchitis. Pneumococcal vaccine had been introduced in 169 Member States by the end of 2025 and global last dose coverage was estimated at 71%. There is great variation between regions. The WHO South-East Asia Region is estimated to have 92% coverage, while it is only 34% in the WHO Western Pacific Region.

Polio is a highly infectious viral disease that can cause irreversible paralysis. In 2025, the coverage of infants receiving their first dose of inactivated polio vaccine (IPV) is estimated at 86%, while 74% of infants around the world received 2 or more doses of IPV. Targeted for global eradication, wild poliovirus remains endemic only in Afghanistan and Pakistan. Until poliovirus transmission is interrupted in these countries, all countries remain at risk of poliovirus importation, particularly those with weak health systems, low immunization coverage, and travel or trade links to affected areas.

Rotaviruses are the most common cause of severe diarrhoeal disease in young children throughout the world. Rotavirus vaccine was introduced in 136 countries by the end of 2025. Global coverage was estimated at 61%.

Rubella is a viral disease which is usually mild in children, but infection during early pregnancy may cause fetal death or congenital rubella syndrome, which can lead to defects of the brain, heart, eyes and ears. Rubella vaccine was introduced in 179 Member States by the end of 2025, including one at the subnational level, and global coverage was estimated at 73%.

Tetanus is caused by a bacterium which grows in the absence of oxygen, for example in dirty wounds or the umbilical cord if it is not kept clean. The spores of *C. tetani* are present in the environment irrespective of geographical location. It produces a toxin which can cause serious complications or death. Maternal and neonatal tetanus persist as public health problems in 8 countries, Afghanistan, Angola, Central African Republic, Nigeria, Pakistan, Papua New Guinea, Somalia, and Yemen.

Yellow fever is an acute viral haemorrhagic disease transmitted by infected mosquitoes. As of 2025, yellow fever vaccine had been introduced in routine infant immunization programmes in 38 of the 40 countries and territories at risk for yellow fever in Africa and the Americas. In these 40 countries and territories, coverage is estimated at 53%.

Key challenges

In 2025, 13.5 million infants did not receive an initial dose of DTP vaccine, pointing to a lack of access to immunization and other health services, and an additional 6 million are partially vaccinated. Of the nearly 20 million un- and under-vaccinated children, around 53% live in 10 countries: Afghanistan, Angola, the Democratic Republic of the Congo, Ethiopia, India, Indonesia, Nigeria, Pakistan, the Philippines and Yemen.

Monitoring data at subnational levels is critical to helping countries prioritize and tailor vaccination strategies and operational plans to address immunization gaps and reach every person with life-saving vaccines...

.....

Statement by Africa CDC on the release of the 2025 WHO/UNICEF Estimates of National Immunization Coverage (WUENIC)

Statement 15 July 2026

[Excerpts]

Today, Africa CDC joins the World Health Organization (WHO), UNICEF, Gavi the Vaccine Alliance and other partners in welcoming the release of the 2025 WHO/UNICEF Estimates of National Immunization Coverage (WUENIC). **These estimates represent far more than annual coverage statistics: they are a measure of the resilience of our health systems, the effectiveness of our primary health care services, and our collective commitment to ensuring that every child, everywhere, has access to life-saving vaccines.**

The latest WUENIC estimates tell a story of resilience, recovery, and unfinished business.

In the African Continent, DTP3 coverage has steadily recovered from a low of 73% in 2021 following the COVID-19 pandemic, reaching 77% in 2025. While this marks important progress, it is still below the pre-pandemic level of 79% in 2019, reminding us that recovery alone is not enough. More concerning is that the world is still off track to achieve the Immunization Agenda 2030 (IA2030) targets. At the midpoint of the decade, there are still 7,128,000 zero-dose children in Africa, 600,000 more than in 2019 and 3.85 million above the trajectory required to halve the number of zero-dose children by 2030. These findings underscore the urgent need to accelerate implementation, strengthen

health systems, and prioritize equitable access to immunization for every child and through the life course...

These figures tell us something important: Africa's immunization challenge now extends well beyond vaccines.

- It is about equity and access.
- It is about strong primary health care and effective delivery of essential services at every contact with the health system.
- It is about reaching communities affected by conflict, displacement, climate shocks, and fragile health systems.
- And ultimately, it is about building resilient health systems capable of protecting populations before, during and after public health emergencies.

The release of the WUENIC estimates reaffirms the importance and timeliness of the Continental Immunization Strategy (CIS), recently endorsed by African Union Member States, as Africa's roadmap for accelerating immunization outcomes for achieving the IA2030 and Addis Declaration on Immunization. This elevates immunization to a top leadership priority across the continent...

The WUENIC data also reinforces several priorities that Africa CDC believes must now define Africa's immunization agenda.

- We must ensure immunization stays a top leadership priority and dramatically accelerate efforts to identify and reach zero-dose and under immunized children through integrated primary health care, community engagement and trust, community health workers, digital innovations, local problem solving, and differentiated and innovative sub-national strategies, including in conflict-affected and fragile communities.
- Member States must continue increasing domestic investment in immunization to ensure sustainable financing and reduce dependence on external resources.
- We must strengthen routine immunization and primary health care as the foundation of epidemic preparedness, response, and resilient health systems.
- Africa must accelerate vaccine manufacturing, pooled procurement, and resilient regional supply chains to improve equitable and sustainable access to vaccines manufactured on the continent.
- We must improve accountability at every level. Data intelligence must increasingly drive decision-making. Through the CIS, Africa CDC is working with Member States to monitor progress through continental scorecards, identify bottlenecks, and accelerate action where it is needed most.

The release of WUENIC is therefore not merely an annual publication of estimates: it is a call to action. Africa must now accelerate towards a transformative agenda...

Let this be our collective resolve: no child should be missed, no community should be forgotten, and no country should be left without the systems, resources, and sovereignty needed to protect its people. Immunization is not only a promise to our children: it is a pillar of Africa's health security, a driver of our prosperity, and a foundation for the future we are determined to build. Together, with urgency, solidarity, and leadership, we can turn this moment into lasting progress for every child, every community, and every nation.

.....
.....

Global Fund

Global Fund Board Takes Strategic Decisions to Navigate a Changing Global Health Landscape

Framework to strengthen risk management and mechanism to enable more sustainable access to health products approved

14 July 2026

GENEVA – The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) concluded its 55th meeting from 9-10 July, **approving two key measures to strengthen the partnership's ability to deliver greater impact in a rapidly changing global health landscape.**

The meeting started with a reflection of the first six months of 2026. In this last year of Grant Cycle 7, cost-effective execution is higher than ever before at this stage, despite multiple disruptive events. Already this year, lenacapavir, the new, game-changing innovation for preventing HIV, has been launched in nine countries. Twenty thousand people received this preventive medicine by the end of May, and by the end of June, this figure more than doubled to 49,000 people. Additional innovations to fight tuberculosis (TB) and malaria – new near-point-of-care tests and spatial repellents – are also moving forward in coordination with countries and technical partners.

As countries prepare for implementation of Grant Cycle 8 (GC8) (2027-2029) in a truncated timeline, **there is intense focus on the difficult trade-offs required from reduced grant allocations.**

Initial funding requests are incorporating the new strategic shifts, including **integration of health services toward a stronger primary healthcare approach and preparations for explicit transition timelines: 61 disease components across 35 countries and three multi-countries will transition out of Global Fund support in GC8 and 21 disease components in 12 countries in Grant Cycle 9.**

"We are at a pivotal moment for global health," said Roslyn Morauta, Chair of the Global Fund Board. **"Countries are facing growing pressures from conflict, extreme weather events and disease outbreaks, while the global financing landscape is becoming more constrained and uncertain.** These challenges make our mission to end the epidemics of HIV/AIDS, tuberculosis and malaria more important, not less. They demand that we make bold choices, manage risk wisely and do everything we can to help countries build stronger, more self-reliant health systems."

Non-Global Fund Financing Procurement

In 2025, the Global Fund managed approximately US\$1.2 billion in procurement, including US\$1.02 billion in grant-funded health products for more than 80 countries through its Pooled Procurement Mechanism. A key part of supporting countries in their transitions is ensuring they have continued access to lifesaving health products negotiated through the Global Fund's market-shaping strategy.

To that end, **the Board approved a new policy to expand access to quality-assured, affordable health products through the Global Fund's procurement platform using financing outside of Global Fund grants, helping countries maintain reliable access to essential medicines and health products as they move toward greater self-reliance.**

To support this initiative, the Board also approved a separate, self-sustaining financing mechanism that **introduces bridge financing for countries that cannot pay upfront. The mechanism will include a pre-financing modality to support countries and reduce access barriers.**

"As countries take on greater responsibility for financing their own health systems, they should not lose access to affordable, quality-assured health products," said Bience Gawanas, Vice-Chair of the Global Fund Board. "Today's decision builds on one of the Global Fund's greatest strengths, enabling us to

support countries and partners with the market-shaping expertise and purchasing power they need to make the transition to more sustainable, resilient health systems.”

Risk Report and Risk Appetite Framework

The Board also updated the organization’s Risk Appetite Framework, reinforcing its commitment to making informed, impact-driven decisions in an increasingly complex operating environment.

The Secretariat presented the 2025 Annual Risk Management Report showing that while the Global Fund remains institutionally resilient and successfully managed major risks throughout 2025, **it is operating in an increasingly volatile and constrained environment that is expected to worsen in 2026.**

The Board approved an updated Risk Appetite Framework to strengthen the Global Fund’s ability to make informed, impact-driven decisions in an increasingly complex operating environment. **The revised framework shifts the focus from monitoring risk to actively managing it, providing clearer governance, more explicit decision-making and earlier identification of emerging risks.**

GC8 Strategy Costing and Operating Expenses

The Global Fund Secretariat presented a plan to deliver the GC8 Strategy within the Board-approved US\$930 million operating expenditure envelope. To maximize the impact of available resources, **the Secretariat proposed a two-track transformation strategy that combines immediate cost-saving measures – including reduced travel, voluntary early separations and optimization of assurance activities – with longer-term changes to the Secretariat’s operating model,** including more tailored country support, greater use of automation and AI, shared service models and other operational efficiencies.

ED Nomination Process

The third Executive Director Selection Process Update reports that the **selection process remains on schedule** and has successfully moved from candidate outreach into the formal assessment phase...

Global Health Ecosystem

A pre-Board panel discussion on the evolving global health ecosystem brought together Dr. Jean Kaseya (the Africa Centres for Disease Control and Prevention), Dr. Joe Phaahla (on behalf of the Eastern Southern Africa & West and Central Africa Board Members), Dr. Edem Adzogenu (AfroChampions/Accra Reset), Katy Kydd Wright (HeAR-CSO Project /Global Fund Advocates Network), Dr. Peter Piot (London School of Hygiene & Tropical Medicine/Accra Reset High-Level Panel), Dr. Bruce Aylward (the World Health Organization) and Dr. Joy Phumaphi (African Leaders Malaria Alliance) to **discuss how global health partnerships must adapt to fiscal constraints, shifting geopolitics and growing demands for country ownership.** Speakers emphasized stronger country and regional leadership, clearer roles and accountability, and the continued relevance of the Global Fund’s multi-stakeholder partnership model, **underscoring the need for more agile, coordinated and country-led approaches to sustain long-term health gains.**

“The global health landscape is changing rapidly, but our shared commitment to saving lives remains constant,” said Peter Sands, Executive Director of the Global Fund. “By strengthening partnerships, supporting country leadership and focusing on innovation and impact, we can work together even more effectively to deliver better health outcomes, ensuring lifesaving innovations reach the people who need them most while maximizing the impact of every dollar.”

The Board discussed the Global Fund’s role in an evolving global health ecosystem, emphasizing the importance of strengthening the organization’s operating model, deepening partnerships and contributing to broader global health reforms. The discussion underscored the importance of building on the Global Fund’s comparative strengths, including country ownership, community leadership, market shaping and pooled procurement – to reduce duplication, strengthen collaboration and maximize impact for the people and communities the partnership serves.

The Board also reviewed progress in strengthening collaboration with key partners, including Gavi, the Vaccine Alliance, to better align support for countries and simplify the way they access health financing and services. The two organizations have identified priority areas for collaboration, including reducing administrative burden, coordinating support for malaria and health systems, exploring joint approaches for TB and new TB vaccines, and improving operational efficiencies. These efforts aim to help countries deliver more integrated, effective and sustainable health programs while advancing broader reforms across the global health ecosystem.

.....
.....

Pandemic Agreement – PABS Annex: IGWG Seventh Meeting

Editor’s Note:

The seventh meeting of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement negotiating the PABS Annex concluded today. As in prior meetings, only the opening session and closing sessions were streamed and recorded as below.

While the meeting webpage does not include any summary of the meeting and no transcript of the DG’s closing remarks have been posted, it is clear from the recorded final session that there was limited progress and no resolution of a number of PABS Annex issues. An eighth meeting was confirmed and will be held 14-18 September 2026.

Seventh meeting of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement

6 – 17 July 2026 Hybrid, Geneva, Switzerland

IGWG7 - Session 2

Item 6 & 7 - Report of the meeting and Closure of the session

17/07/2026 - 14:30-15:35

IGWG7 - Session 1

Item 1 - Opening of the session and adoption of the agenda and programme of work

Recording

06/07/2026 - 09:15-10:55

[A/IGWG/7/1 Rev.1](#) Agenda

[A/IGWG/7/2 Rev.1](#) Draft revised programme of work

[A/IGWG/7/3 Rev.1](#) Working modalities and updated timeline and deliverables of the open-ended Intergovernmental Working Group

[Draft PABS Annex text](#)

.....
.....
.....

Ebola – Bundibugyo virus disease (BVD) – PHEIC/PHECS

WHO

Disease Outbreak News

17 July 2026 | Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda

Situation at a glance

The Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo remains active, with sustained transmission driving increases in reported cases and deaths. As of 15 July 2026, a cumulative total of 2124 confirmed cases, including 828 deaths, have been reported from the Democratic Republic of the Congo. On 13 July 2026, German authorities informed WHO of a laboratory-confirmed case of Ebola disease caused by Bundibugyo virus in a humanitarian worker from the United States of America who was medically evacuated from the Democratic Republic of the Congo. This is the second United States citizen to be treated in Germany, reflecting the ongoing international response efforts. In Uganda no new cases have been reported since 21 June 2026. The most recent case was discharged from the treatment centre on 16 July after two negative tests results. The country has therefore begun the 42-day period of enhanced surveillance required before the end of the outbreak can be declared. National authorities in Uganda and the Democratic Republic of the Congo, in collaboration with WHO and partners, continue to implement extensive response measures. A regional preparedness and prioritization framework continues to guide readiness activities across the African Region...

WHO risk assessment

On 6 June 2026, WHO reassessed the risk of the outbreak of BVD to incorporate newly available information and align with the WHO Temporary Recommendations. The risk for countries sharing land borders with countries with documented Bundibugyo virus detection, the Democratic Republic of the Congo and Uganda at the time of assessment, has been separated from the risk for other countries in the African Region.

The risk in the Democratic Republic of the Congo remains assessed as very high due to ongoing transmission and the continued expansion of the outbreak into new health zones, increasing the potential for further national and regional spread.

The risk in Uganda is still assessed as high due to confirmed cross-border spread through imported cases and ongoing epidemiological links along the eastern Democratic Republic of the Congo–western Uganda corridor, which has historically been affected by Ebola outbreaks, including Bundibugyo virus and Sudan virus disease.

The risk for countries sharing land borders with countries reporting BDBV detection is assessed as high due to sustained population mobility linked to cross-border trade and mining activities, variation in capacities and experience of BVD response, and variable levels of readiness.

The risk for the rest of the African region and at the global level is assessed as low...

WHO advice

WHO advises against any restriction of travel to, or trade with, the Democratic Republic of the Congo or Uganda based on the currently available information. WHO continues to closely monitor and, where necessary, verify travel and trade measures in relation to this event...

Uganda begins countdown to end of Ebola outbreak

16 July 2026 | *News Release* WHO African Region AFRO

Kampala—Uganda has today entered the 42-day countdown to the end of its Ebola outbreak after the last confirmed case tested negative for the virus for a second time and was discharged from care, marking an important milestone in the country's response.

The 42-day countdown, equivalent to two maximum incubation periods for Bundibugyo virus disease, is the established phase before an outbreak can be declared over, provided no new confirmed cases are detected during this period.

Uganda declared the outbreak on 15 May 2026 and as of 16 July 2026, 20 confirmed cases and two deaths have been reported. Fifteen cases were the result of importation from the Democratic Republic of the Congo and five were locally acquired...

WHO target product profile for Bundibugyo virus disease vaccines, 14 July 2026

WHO 14 July 2026 | *Guidance (normative)*

Overview

Bundibugyo virus disease, which is caused by Bundibugyo virus, is a severe filovirus infection with epidemic potential that requires the development of safe and effective medical countermeasures to reduce morbidity, mortality and transmission during outbreaks. In response to the 2026 Public Health Emergency of International Concern and the urgent need for Bundibugyo virus-specific vaccines, this document presents the World Health Organization target product profile (TPP) for vaccines against Bundibugyo virus disease. The TPP defines the minimum and preferred characteristics for vaccine candidates to guide research, development and regulatory pathways while supporting preparedness for future outbreaks.

The Diagnostic testing for Ebola disease and Marburg virus disease: interim guidance, 9 July 2026

WHO 13 July 2026 | *Guidance (normative)*

Overview

Rapid diagnosis of Ebola disease (EBOD) and Marburg virus disease (MVD) is critical to provide timely and appropriate care and stop transmission. These diseases can be difficult to clinically distinguish from other infectious diseases such as malaria, and countermeasures, including vaccines and therapeutics, are available specifically for some species of orthoebolaviruses and orthomarburgviruses, meaning that laboratory confirmation is very important. Handling of samples from patients with suspected EBOD or MVD requires appropriate biosafety measures.

This document constitutes an update to the *Diagnostic testing for Ebola and Marburg virus diseases: interim guidance, 20 December 2024*.

It provides interim guidance to laboratory personnel, clinicians, health workers, public health officials, outbreak response teams, and other stakeholders involved in the diagnosis and care of patients with suspected or confirmed EBOD or MVD, from specimen collection through to diagnostic analysis and reporting.

.....
.....

Africa CDC

Joint Statement

Africa CDC and SIMBA integrate Biological Security into the Response to the Bundibugyo virus disease (BVD) Outbreak

15 July 2026

...The *Signature Initiative to Mitigate Biological Threats in Africa* (SIMBA) provides a framework for integrating biosecurity in public health response to outbreaks of high consequence pathogens. Through its established partnerships, trusted relationships, technical expertise, and sustained capacity-building efforts, SIMBA is well positioned to support the current BVD outbreak response activities, develop local context-centred preparedness capabilities to respond to future outbreaks, while ensuring that biological security considerations are integrated into public health operations from the outset.

In partnership with WHO, Africa CDC, and the International Criminal Police Organization (INTERPOL), as well as other African partners, international organizations and donors, and in line with the Biological and Toxin Weapons Convention (BTWC), SIMBA is willing to support sustainable and nationally owned

approaches to managing biological risks and strengthening preparedness for outbreaks of epidemic-prone diseases such as Ebola disease...

Press Releases

Bundibugyo Ebola Virus Outbreak: Launch of the EBO-PEP Trial to Protect High-Risk Contacts

14 July 2026

The National Institute for Biomedical Research (INRB) in Kinshasa, the ANRS Emerging infectious diseases / Inserm and the NGO ALIMA, alongside all their partners, are launching EBO-PEP, the first clinical trial to assess the efficacy of post-exposure prophylaxis (PEP) with the antiviral obeldesivir against the current Bundibugyo Ebola virus outbreak. The trial begins on 14 July 2026 in the Democratic Republic of the Congo and Uganda....

.....
.....

CEPI

CEPI-backed Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group

Jodie Rogers 12th July 2026

A CEPI-backed vaccine candidate developed by the University of Oxford's Oxford Vaccine Group has become the first Bundibugyo ebolavirus vaccine to enter Phase 1 clinical trials, in a rapid response to the deadly outbreak spreading across the Democratic Republic of the Congo (DRC) and Uganda.

Conducted in Oxford, UK, the trial will assess the safety and immune response of the vaccine candidate – known as ChAdOx1 BDBV – in 50 healthy adults aged 18-55 years. Following conditional regulatory approval by the UK's Medicines Healthcare products and Regulatory Agency (MHRA), recruitment of volunteers into the study is now underway. Vaccinations are expected to begin in the coming weeks following full regulatory approval...

Dr Nicole Lurie, Executive Director Preparedness and Response at CEPI, described the rapid progress as a pivotal milestone in the response effort. "Every step brings a safe and effective vaccine closer and helps strengthen our ability to protect vulnerable communities, save lives and bring this outbreak under control", Dr Lurie said.

Just two weeks after the outbreak was declared, **CEPI and its long-standing partners the University of Oxford and Serum Institute of India kicked off a US\$8.6 million partnership to urgently advance the development of the investigational vaccine into clinical trials.**

"Our team has worked tirelessly with global partners to develop a candidate ChAdOx BDBV vaccine, demonstrating how collaborative partnerships can enable rapid response in the face of rapidly evolving outbreaks", explained Professor Teresa Lambe OBE, Calleva Head of Immunology at the Oxford Vaccine Group and Pandemic Sciences Institute, and the study's Lead Scientific Investigator.

The ChAdOx1 BDBV vaccine was developed by scientists at the University of Oxford's Oxford Vaccine Group and Pandemic Sciences Institute and uses the same viral vector platform as the Oxford/AstraZeneca COVID-19 vaccine, which is estimated to have saved over six million lives during its first year of use.

It is one of four initial Bundibugyo vaccine candidates in CEPI's portfolio as the organisation seeks to advance at least two vaccines to emergency use authorisation, potentially helping to curb the

outbreak and save lives. By backing multiple candidates in parallel, CEPI spreads financial risk, maximises development speed and increases the likelihood of success.

The Serum Institute of India (SII) has manufactured and stockpiled approximately 620,000 doses of the ChAdOx1 BDBV vaccine candidate in two weeks for potential future use and has supplied 4,000 investigational doses for this Phase I trial...

Subject to regulatory approval, preparations are also underway for further clinical studies with partners, including those at the Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit.

If Phase 1 trials are successful, CEPI anticipates working with the University of Oxford and SII to support late-stage trials to generate data for emergency use authorisation or licensure...

.....
.....
.....

Polio – PHEIC

[Polio this week](#) [15 July 2026]

Headlines [Selected]

:: GPEI leadership in endemic countries: polio eradication and strengthening health systems go hand in hand

Last week, the Polio Oversight Board (POB) of the Global Polio Eradication Initiative (GPEI) met with programme and public health leaders in both [Afghanistan](#) and [Pakistan](#). Leaders from Rotary International, WHO, UNICEF, Gavi and KSR relief met with frontline health workers, religious leaders, government representatives, donors and partners, to underscore the urgent need to eradicate polio while protecting essential health services. Throughout the visits, the message that emerged was very clear: end polio and strengthening health systems go hand in hand. With sustained commitment and support, efforts can protect children, strengthen communities and advance health security across the region.

:: New outbreak response standards to stop polio faster

As the world moves closer to polio eradication, stopping outbreaks quickly and decisively has never been more important. To reflect evolving epidemiology, new scientific evidence and years of operational experience, the Global Polio Eradication Initiative has updated its outbreak response [Standard Operating Procedures \(SOPs\)](#). The updated SOPs sharpen how countries detect, assess and respond to poliovirus outbreaks — with a particular focus on the type 2 outbreaks that now account for most global transmission. They introduce clearer outbreak definitions, stronger risk assessment, and more tailored response strategies, helping programmes close immunity gaps faster and prevent outbreaks from becoming prolonged. For a high-level overview of polio outbreaks and how to stop them, partners at the UN Foundation have developed a short explainer fact sheet [here](#).

Summary of new polioviruses this week:

- :: Afghanistan : four WPV1 cases and 12 WPV1-positive environmental samples
- :: Pakistan: one WPV1-positive environmental sample
- :: Chad: one cVDPV2 case
- :: DR Congo: two cVDPV2 cases
- :: Ethiopia: two cVDPV1 cases
- :: Nigeria: one cVDPV3 case

:: South Sudan: one cVDPV1 cas

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)
:: [WHO](#)
:: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
:: [Organization Announcements](#)
:: [Journal Watch](#)
:: [Pre-Print Servers](#)
:: [Think Tanks](#)
:: [Public Consultations/Call for Inputs/Call for Papers](#)

.....
.....

WHO & Regional Offices [18 July 2026]

<https://www.who.int/news>

Selected News/Announcements/Statements

15 July 2026 *Joint News Release*

[Global childhood immunization coverage inches forward despite conflict and hesitancy – UNICEF, WHO](#)

14 July 2026 *Departmental update*

[WHO issues updated dosing guidance for antiretroviral medicines used in newborns, infants and children](#)

.....

WHO Vaccines and Immunization [IVB]

https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1

News

15 July 2026 *Joint News Release*

[Global childhood immunization coverage inches forward despite conflict and hesitancy – UNICEF, WHO](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: [17 July 2026 | News Release](#)

[Mental health leaders commit to expanding rights-based care across West and Central Africa](#)

:: [16 July 2026 | News Release](#)

[Uganda begins countdown to end of Ebola outbreak](#)

:: [14 July 2026 | Feature Story](#)

[Protecting girls from cervical cancer in The Gambia](#)

WHO Region of the Americas PAHO

:: [16 Jul 2026](#)

PAHO Director and President of El Salvador highlight progress in disease elimination and strengthening the health system

San Salvador, El Salvador, 16 July 2026 (PAHO) – The Director of the Pan American Health Organization (PAHO), Dr. Jarbas Barbosa, met with the President of the Republic of El Salvador, Nayib Bukele, during an official visit aimed at strengthening cooperation in strategic health areas and recognizing the country's significant achievements. During...

:: 15 Jul 2026

WHO and UNICEF estimates show routine immunization has rebounded in the Americas, but declining measles coverage leaves communities vulnerable to outbreaks

The Region has surpassed pre-pandemic routine vaccination levels, but immunity gaps continue to fuel measles outbreaks, particularly among unvaccinated and under-vaccinated communities
Washington, D.C., 15 July 2026 (PAHO) – Childhood vaccination in the Americas continued to recover in 2025, with the number of unvaccinated children under the age of...

:: 15 Jul 2026

PAHO/WHO supports health response to Venezuela earthquake with the delivery of 27 tonnes of medicines and medical supplies

Maiquetía, Venezuela, 15 July 2026 (PAHO) – The Pan American Health Organization/World Health Organization (PAHO/WHO), in coordination with the Ministry of Popular Power for Health (MPPH), has delivered 27 tonnes of medicines, medical supplies and specialized equipment for distribution to hospitals across Venezuela. The shipment will strengthen...

:: 14 Jul 2026

Venezuela earthquake health response enters early recovery phase as focus shifts to restoring essential health services

Washington, D.C., 14 July 2026 (PAHO) – Nearly three weeks after the devastating earthquakes struck Venezuela on 24 June, the health response is entering a critical early recovery phase focused on restoring essential health services, strengthening referral networks and preventing secondary public health emergencies, according to PAHO's latest...

WHO South-East Asia Region SEARO

:: 15 July 2026 *News release*

WHO calls for renewed efforts to reach every child with life-saving vaccines

WHO European Region EURO

:: 16 July 2026 *News release*

Planning for a warmer world

:: 15 July 2026 *Media release*

WHO brings 37 countries together in Lisbon to get AI governance right and make it work for every patient

WHO Eastern Mediterranean Region EMRO

:: Syria's second FETP cohort trains to strengthen disease surveillance and outbreak response

15 July 2026

:: WHO launches an ECHO-funded project to expand lifesaving health and mental health services for Sudanese refugees in southern Libya

14 July 2026

WHO Western Pacific Region

:: 15 July 2026 *Media release*

Uneven progress, significant gaps: New immunization estimates must accelerate urgent action...

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

No new digest content identified.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health

[17 July 2026 | Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda](#)

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Volume 101 Issue 28 Epidemiological Week 28 (6 July – 12 July 2026)

<https://iris.who.int/server/api/core/bitstreams/bae50897-d67b-4cd0-a9f0-792fc346ce00/content>

:: Highlighted signals and events

:: SARS-CoV-2 (COVID-19): global epidemiological update

:: WHO Alliance for the Global Elimination of Trachoma: progress report on elimination of trachoma, 2025–2026

.....

New WHO Publications

<https://www.who.int/publications>

Selected

17 July 2026

[Eleventh Meeting of the WHO South-East Asia Regional Verification Commission for Measles and Rubella Elimination](#)

15 July 2026

[Root cause analysis of low yellow fever vaccination coverage: user manual and questionnaire](#)

14 July 2026

[WHO target product profile for Bundibugyo virus disease vaccines, 14 July 2026](#)

14 July 2026

[Guideline on doxycycline post-exposure prophylaxis for sexually transmitted infections among men who...](#)

13 July 2026

[The Diagnostic testing for Ebola disease and Marburg virus disease: interim guidance, 9 July 2026](#)

.....

.....

.....

Africa

Africa CDC [18 July 2026]

<https://africacdc.org/>

News & Updates [Selected]

[Africa CDC Congratulates Green Climate Fund on Unlocking \\$4 Billion in New Climate Finance Capacity](#)

16 July 2026

Joint Statement

[Africa CDC and SIMBA integrate Biological Security into the Response to the Bundibugyo virus disease \(BVD\) Outbreak](#)

15 July 2026

Statement

[Statement by Africa CDC on the release of the 2025 WHO/UNICEF Estimates of National Immunization Coverage \(WUENIC\)](#)

15 July 2026

Press Releases

[Bundibugyo Ebola Virus Outbreak: Launch of the EBO-PEP Trial to Protect High-Risk Contacts](#)

14 July 2026

African Medicines Agency [18 July 2026]

<https://au-ama.africa/news-events/>

Latest News & Events

[African Medicines Agency and Medicines for Africa Join Forces to Protect Patients from Unsafe Medicines Across Africa](#)

July 15, 2026

Under the MoU, AMA will leverage the expertise of MFA in advocacy and communication to support National Regulatory Authorities (NRAs) in Africa in their initiatives to combat substandard and falsified medical products.

.....
.....

China – CDC+

National Health Commission of the People's Republic of China [18 July 2026]

<http://en.nhc.gov.cn/>

News

[China targets average life expectancy of 80 by 2030 in new five-year health plan](#)

Updated: 2026-07-16 | Xinhua

National Medical Products Administration – PRC [18 July 2026]

<http://english.nmpa.gov.cn/>

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (8)

<https://weekly.chinacdc.cn/article/current>

2026 Vol. 8 No. 29 [PDF](#)

Outbreak Reports

[First Human Infection with Influenza A\(H1N2\)v Virus — Yunnan Province, China, 2026](#)

Lihua Chen, Yaoyao Chen, Xiaoyu Han, Ruize Ni, Ming Zeng, Jie Deng, Chunyuan Deng, Guijing Chen, Xiaoqing Fu, Jibo He, Chunrui Luo

.....
.....

Europe

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

[Drug-resistant gonorrhoea on the rise in Europe, ECDC warns](#)

16 July 2026

Publications

Surveillance and monitoring

[Communicable disease threats report, 13 - 17 July 2026, week 29](#)

17 July 2026

Surveillance and monitoring

[Surveillance of West Nile virus infections in humans, weekly report](#)

17 July 2026

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

[EMA and EISMEA boost cooperation to accelerate health innovations](#)

15 July 2026

Cooperation will encourage the development of innovative medicines and health solutions for patients

EMA and the European Innovation Council and SMEs Executive Agency (EISMEA) have strengthened their cooperation in support of health innovation in the European Union (EU). Today, EMA's Executive Director Emer Cooke and EISMEA's Director Momchil Sabev signed a letter of intent to reinforce their continuing efforts in helping innovators better understand EU regulatory requirements and prepare health technologies for successful development.

.....
.....

India

National Centre for Disease Control

Directorate General of Health Services, Ministry of Health & Family Welfare

Announcements

No new digest content identified.

.....
.....
.....

U.S. Immunization and Public Health Governance/Policy/Funding

Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external analysis and comment, either boxing or indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive

Executive Branch - White House, State, HHS, FDA, CDC+ White House

Presidential Actions – Executive Orders; Memoranda; Proclamations
No new digest content identified.

Department of State

Press Releases - Selected
Media Note

The United States Leverages American Private Sector to Save Lives and Treat Global Malnutrition

July 14, 2026

As part of the United States government's ongoing humanitarian assistance leadership, the Department of State entered a new two-year partnership with Operation End Starvation to provide life-saving nutrition assistance to populations in need. Through the Department's Bureau of Disaster and Humanitarian Response, the United States intends to provide \$100 million over the next two years to Operation End Starvation, an American non-governmental organization and public-private partnership launched to combat global child mortality. The U.S. partnership with Operation End Starvation will drive life-saving nutrition interventions globally and reach children at risk of or suffering from severe acute malnutrition, one of the world's most urgent humanitarian challenges...

HHS

Press Room - Selected
No new digest content identified.

NIH

News Releases
No new digest content identified.

FDA

Press Announcements
No new digest content identified.

FDA CBER

What's New for Biologics
No new digest content identified.

FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee]

Advisory Committee Calendar

No future meeting dates posted.

FDA Pediatric Advisory Committee Meeting

Advisory Committee Calendar

No future meeting dates posted.

CDC

<http://www.cdc.gov/media/index.html>

Latest News - Selected

No new digest content identified.

CDC – Immunization Safety Office (ISO)

<https://www.cdc.gov/vaccine-safety-systems/about/cdc-monitoring-program.html>

No new digest content identified [last updated August 7, 2024]

ACIP

2026 Meetings Schedule

- March 18-19 (Due to ongoing litigation, this meeting is cancelled)
- June 24-26 (Due to ongoing litigation, this meeting is cancelled)
- October 21-23

National Vaccine Advisory Committee (NVAC)

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No 2025 or 2026 meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)

<https://www.hrsa.gov/advisory-committees/vaccines/meetings>

Next ACCV meetings – TBD

MMWR Weekly

<https://www.cdc.gov/mmwr/index2026.html>

July 16, 2026 / No. 27

[PDF of this issue](#)

:: [Genotype-Specific Detection of Measles Virus Using Wastewater Surveillance — Wisconsin, February 2026](#)

:: [Increase in Disseminated Gonococcal Infections — Alaska, 2023–2024](#)

:: [Erratum: Vol. 75, No. SS-4](#)

.....

National Science Foundation/NSF

News

No new digest content identified.

.....

U.S. Congress

House

No new digest content identified.

Senate

Senate Health, Education, Labor and Pensions committee

:: [Nominations of Sean Kaufman to be Assistant Secretary for Preparedness and Response for the Department of Health and Human Services and Erica Schwartz to be Director of the Centers for Disease Control and Prevention](#)

07/15/26

.....

Supreme Court, Federal & Appellate Courts

O'Neill Institute – Health Care Litigation Tracker [Georgetown University]

<https://litigationtracker.law.georgetown.edu/>

No new digest content identified.

.....
.....
.....

U.S. Medical, Scientific, Professional Societies; Health Organizations

This inventory is evolving and may not capture all instances of relevant comment and analysis.

American Academy of Family Physicians (AAFP)

<https://www.aafp.org/news/media-center.html>

(Accessed 18 July 2026)

No new digest content identified.

American Academy of Pediatrics (AAP)

<https://www.aap.org/en/news-room/news-releases-from-the-aap/>

(Accessed 18 July 2026)

News

[AAP President Dr. Andrew Racine Co-Authors Critique of U.S. Cuts to Medicaid for Children, Denouncing their Impact to Nation's Health](#)

July 15, 2026

American Academy of Pediatrics President Andrew D. Racine, MD, PhD, FAAP, and Jonathan H. Gruber, PhD, break down the short- and long-term impacts of cuts to Medicaid unfolding under a law enacted by Congress in a new viewpoint published in the journal JAMA this week. Medicaid serves as the largest public health insurance program in the United States, covering 85 million people – including 40 million children.

American College of Physicians (ACP)

<https://www.acponline.org/more-acp-news>

(Accessed 18 July 2026)

No new digest content identified.

America's Health Insurance Plans (AHIP)

<https://www.ahip.org/news>

(Accessed 18 July 2026)

News

No new digest content identified.

American Geriatrics Society (AGS)

<https://www.americangeriatrics.org/media-center>

(Accessed 18 July 2026)

Recent Press Releases

No new digest content identified.

American Medical Association (AMA)

<https://www.ama-assn.org/press-center>

(Accessed 18 July 2026)

Press Releases

No new digest content identified.

American Osteopathic Association (AOA)

<https://osteopathic.org/news/>

(Accessed 18 July 2026)

Latest News

No new digest content identified.

American Public Health Association (APHA)

<https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc>

(Accessed 18 July 2026)

OMB's Proposed Federal Financial Assistance Rule Threatens the Availability and Accessibility of Vital Health Care Services for Medically Underserved and Vulnerable Communities and Populations

July 14, 2026

A proposed rule issued by the Office of Management and Budget (OMB) would authorize federal agency leadership to terminate federal funding at their sole discretion, effectively overriding merit review. This marks a significant and troubling escalation in the politicization of the federal grantmaking process.

Infectious Diseases Society of America (IDSA)

<https://www.idsociety.org/>

(Accessed 18 July 2026)

Statement on order blocking U.S. travelers' return from the Democratic Republic of the Congo

Last Updated July 17, 2026

The Trump Administration's decision to further complicate U.S. travelers' return from a country facing an Ebola outbreak blatantly ignores the world-class infectious diseases care available right here at home, by the United States' National Emerging Special Pathogens Training and Education Center network and the U.S. Regional Emerging Special Pathogen Treatment Centers.

Delaying the return of U.S. citizens who deploy to support the response to the Ebola outbreak leaves them without the benefit of world-class specialized health care provided by NETEC and the RESPTCs — a system the U.S. has spent more than a decade and hundreds of millions of dollars to develop. This policy will likely deter Americans from traveling to the Democratic Republic of the Congo to help stop the largest outbreak of this deadly disease in history...

National Foundation for Infectious Diseases (NFID)

<https://www.nfid.org/news-updates/>

(Accessed 18 July 2026)

News and Updates

No new digest content identified.

National Medical Association (NMA)

<https://nmanet.org/blog/>

(Accessed 18 July 2026)

Latest News

No new digest content identified.

Pediatric Infectious Diseases Society (PIDS)

<https://pids.org/news-announcements/>

(Accessed 18 July 2026)

News & Announcements

No new digest content identified.

Society for Healthcare Epidemiology of America (SHEA)

<https://shea-online.org/news/>

(Accessed 18 July 2026)

No new digest content identified.

Society for Maternal-Fetal Medicine (SMFM)

<https://www.smfm.org/>

(Accessed 18 July 2026)

News

No new digest content identified.

.....
.....

Civil Society – Individuals, Organizations, Institutions [Selected]

.....

Kaiser Family Foundation/KFF [18 July 2026]

https://www.kff.org/search/?post_type=press-release

Research, Analysis

KFF Tracker: U.S. Global Health Programs by Country and Region

Jul 16, 2026 *Fact Sheet*

This resource provides an overview of where the U.S. operates bilateral global health programs by country and region.

.....

Vaccine Integrity Project – CIDRAP [to 18 July 2026]

<https://www.cidrap.umn.edu/vaccine-integrity-project>

Announcements, Viewpoints

No new digest content identified.

.....

Center for Vaccine Ethics & Policy - GE2P2 Global Foundation [to 18 July 2026]

<https://centerforvaccineethicsandpolicy.net/>

No new digest content identified.

.....

Paul Offit, MD – *Beyond the Noise*

Substack: <https://pauloffit.substack.com/>

No new digest content identified.

.....

.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....

.....

Organization Announcements

Paul G. Allen Frontiers Group [18 July 2026]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

Gates Foundation [18 July 2026]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

[Statement on Warren Buffett's Giving](#)

Statement Jul 14, 2026

The Gates Foundation is grateful to [Warren Buffett](#) for his decades of support for our work. His gifts, totaling more than \$47 billion, have helped us expand and deliver on the foundation's mission to improve health and opportunity for people around the world. The foundation continues from a position of financial strength to advance our work through 2045, supported by Bill's \$200 billion commitment.

CARB-X [18 July 2026]

<https://carb-x.org/>

News

07.15.2026 |

[CARB-X announces Dr. Richard Alm as next Chief of Research & Development](#)

CARB-X today announced that Richard Alm, Ph.D., has been appointed Chief of Research and Development (R&D) following a competitive global recruitment process.

Chan Zuckerberg Initiative [18 July 2026]

<https://chanzuckerberg.com/newsroom/>

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [18 July 2026]

<http://cepi.net/>

News

[CEPI-backed Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group](#)

Jodie Rogers 12th July 2026

A CEPI-backed vaccine candidate developed by the University of Oxford's Oxford Vaccine Group has become the first Bundibugyo ebolavirus vaccine to enter Phase 1 clinical trials, in a rapid response to the deadly outbreak spreading across the Democratic Republic of the Congo (DRC) and Uganda.

Conducted in Oxford, UK, the trial will assess the safety and immune response of the vaccine candidate – known as ChAdOx1 BDBV – in 50 healthy adults aged 18-55 years. Following conditional regulatory approval by the UK's Medicines Healthcare products and Regulatory Agency (MHRA), recruitment of volunteers into the study is now underway. Vaccinations are expected to begin in the coming weeks following full regulatory approval...

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 18 July 2026]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [18 July 2026]

<https://www.darpa.mil/news>

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases Initiative [18 July 2026]

<https://dndi.org/press/press-releases/>

Press Releases

Press releases 13 Jul 2026

[DNDi welcomes continued GHIT support for collaboration on dengue and Zika virus drug discovery with Eisai and new partner, the Japan Institute for Health Security](#)

Press releases 13 Jul 2026

[DNDi welcomes GHIT support to advance novel oral drug candidate for leishmaniasis, accelerating progress towards elimination goals](#)

Duke Global Health Innovation Center [18 July 2026]

<https://dukeghic.org/>

News

[ALIGN Case Studies – Full Series](#)

15 Jul 2026

The series is produced by the ALIGN Consortium as part of our shared learning agenda. Each case study—featuring Thailand, the Netherlands, and Ghana—examines how a particular country has

navigated the persistent challenge of introducing new health innovations—how it evaluates, prioritizes, finances, and sustains them within real fiscal and political constraints. Our aim is not to rank systems or prescribe a single model, but to understand how reform actually unfolds: what enables it, what constrains it, and what does and does not transfer across contexts. These cases inform ALIGN’s work alongside national partners and are offered in the spirit of mutual learning. We welcome reactions, corrections, and counter-examples from colleagues who know these systems first-hand.

EDCTP [18 July 2026]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [18 July 2026]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [18 July 2026]

<http://www.euvaccine.eu/>

News

No new digest content identified.

Fondation Merieux [18 July 2026]

<http://www.fondation-merieux.org/>

Actualités

No new digest content identified.

Gates Medical Research Institute [18 July 2026]

<https://www.gatesmri.org/news>

News: Articles and Publications

[Gates Medical Research Institute and the Serum Institute of India Reach Agreement for the Manufacture of M72/AS01E Tuberculosis Vaccine Candidate, Pending Successful Phase 3 Outcomes](#)

July 16, 2026 *Press Release*

The Gates Medical Research Institute (Gates MRI) has reached a milestone agreement with the Serum Institute of India Private Limited (SII) to manufacture M72/AS01E, a novel tuberculosis (TB) vaccine candidate.

Gavi [to 18 July 2026]

<https://www.gavi.org/>

News Releases, VaccinesWork

[Strong progress in lower-income countries underscores need for sustained investment in](#)

immunisation

Geneva, 15 July 2026 – Each year WHO and UNICEF release global and national routine immunisation coverage estimates (WUENIC).

Immunisation in the lowest-income countries is supported by Gavi, the Vaccine Alliance – a partnership that helps vaccinate more than half the world's children, and includes WHO and UNICEF as core members.

Below, Gavi analyses what the 2025 WUENIC data says about the state of immunisation in the 57 low- and lower-middle income countries it supports...

GE2P2 Global Foundation [18 July 2026]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements/Digests

:: **Vaccines and Global Health: The Week in Review** - Current edition

:: **Public Consultations Watch :: Global Calls for Input/Public Comment – 19 June 2026**

GHIT Fund [18 July 2026]

<https://www.ghitfund.org/newsroom/press>

Press Releases

July 13, 2026

Total Investment of Approx. USD 18 Million in Malaria, Tuberculosis and NTD R&D Projects with Partners Including Shionogi, Eisai, Nagasaki, Ehime and Niigata University

Global Fund [to 18 July 2026]

<https://www.theglobalfund.org/en/news/>

News Releases

16 July 2026

Global Fund Approves Emergency Funding for Malaria Prevention to Safeguard Ebola Response in the Democratic Republic of the Congo

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has approved US\$4.6 million in emergency funding to support an intensified malaria response in DRC to aid their Ebola response.

15 July 2026

Global Fund Approves Emergency Funding to Protect HIV and TB Services in Venezuela Following Earthquakes

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has approved US\$1.77 million in emergency funding to help protect lifesaving HIV and tuberculosis (TB) services in Venezuela following two powerful earthquakes that struck the ...

14 July 2026

Global Fund Board Takes Strategic Decisions to Navigate a Changing Global Health Landscape

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [18 July 2026]

<https://www.glopid-r.org/>

News & Event

No new digest content identified.

Hilleman Laboratories [18 July 2026]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [18 July 2026]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [18 July 2026]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [18 July 2026]

<https://www.iavi.org/>

Press Releases, Features

In The News

[HIV vaccine candidates reach milestone in primates](#)

Chemical & Engineering News

July 9, 2026

INSERM [18 July 2026]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 18 July 2026]

<https://www.ich.org/page/public-consultations>

News/Pubs/Press Releases [Selected]

No new digest content identified.

ICRC [to 18 July 2026]

<https://www.icrc.org/en/news>

Latest press releases and statements

Article 17-07-2026

"Humanitarian challenges today are global, and so must be the solutions"

Launch of the 2025 Beijing Symposium Report

As technologies reshape conflict and humanitarian action across borders, today's humanitarian challenges are inherently global, demanding dialogue that brings together diverse perspectives and expertise. The article highlights key insights from the Symposium on the Responsible Use of Technology in Humanitarian Action, held in Beijing in December 2025, presenting shared dilemmas, emerging challenges, and avenues for continued engagement.

IFFIm [18 July 2026]

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 18 July 2026]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press releases

No new digest content identified.

IPPS - International Pandemic Preparedness Secretariat [18 July 2026]

<https://ippsecretariat.org/news/>

News

Ebola (Bundibugyo) Day 60 – Tracking Progress on Medical Countermeasures

July 16, 2026

100 Days Mission Ebola Clock: Day 60 (minor update)

Institut Pasteur [18 July 2026]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

InterAcademy Partnership (IAP)

<https://www.interacademies.org/news/press-releases>

News

No new digest content identified.

ISC / International Science Council [to 18 July 2026]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

news

13 July 2026 - 11 min read

Science as a human right: call for ISC Member endorsement

In November 2024, the International Science Council published its interpretation of the Right to Participate in and Benefit from Science, with the aim of clarifying what universal human rights mean for the practice of science and for the use of scientific knowledge.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News, Resources

Innovation challenge: Call for applications

July 14, 2026

IVAC [18 July 2026]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [18 July 2026]

<http://www.ivi.int/>

IVI News & Announcements

IVI remembers Prof. Wan Kyoo Cho

13 July 2026 — The International Vaccine Institute (IVI) mourns the passing of Prof. Wan Kyoo Cho, one of IVI's founders and a longstanding champion of vaccine science and global health. During his distinguished career, Prof. Cho played a pivotal role in advancing the vision that led to the establishment of IVI in Seoul, Republic of Korea, and helped lay the foundation for an institution dedicated to protecting the world's most vulnerable populations from infectious diseases...

Johns Hopkins Center for Health Security [18 July 2026]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

Robert Wood Johnson Foundation [to 18 July 2026]

<https://www.rwjf.org/en/about-rwjf/newsroom.html>

Latest News and Highlights

No new digest content identified.

MSF/Médecins Sans Frontières [to 18 July 2026]

<http://www.msf.org/>

Latest [Selected Announcements]

DRC Ebola outbreaks

DRC Ebola outbreak response needs urgent scale-up after two months

Press Release 15 Jul 2026

National Academy of Medicine - USA [to 18 July 2026]

<https://nam.edu/programs/>

News, Stories, Insights

No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM] - USA [to 18 July 2026]

<https://www.nationalacademies.org/newsroom>

News

[The Science of Extreme Event Attribution — Which Analyzes Climate Change's Influence on Specific Weather Events — Has Advanced, But Challenges Remain](#)

News Release Last update July 15, 2026

PATH [18 July 2026]

<https://www.path.org/media-center/>

Newsroom [Selected]

[Half of Africa's approved diagnostics for six priority epidemic diseases are not accessible to primary health care facilities, new report finds](#)

Since 2015, funding to develop tests for these diseases has fallen by more than half, even as outbreaks like the 2026 Bundibugyo ebolavirus keep occurring.

Published: July 2026

Press Release

[PATH and Unitaid partner with GiveWell to strengthen integrated HIV and syphilis testing for mothers, newborns, and their families](#)

An initiative between PATH, Unitaid, and GiveWell will advance dual testing for HIV and syphilis via primary health care platforms across five countries in Africa.

Published: July 2026

Press Release

Rockefeller Foundation [to 18 July 2026]

<https://www.rockefellerfoundation.org/>

News and Announcements

[As Ebola Surges, 3 in 4 Americans Back Restoring U.S. Aid to Fight It, per New Echelon Poll Commissioned by Rockefeller Foundation](#)

Press Releases Published Date July 08, 2026

:: Conducted ahead of America's 250th anniversary, the survey finds nine in ten Americans (90%) across the political spectrum support funding programs to prevent disease outbreaks abroad, the highest-testing program area in the survey.

:: Those who primarily support President Trump are the least concerned about Ebola spreading to the U.S., yet more than one in two (52%) back restoring U.S. aid to contain the outbreak, along with 60% of Republican-leaning and 89% of Democrat-leaning.

Sabin Vaccine Institute [18 July 2026]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified

UNAIDS [18 July 2026]

<http://www.unaids.org/en>

News, Stories, Updates

No new digest content identified.

UNICEF [to 18 July 2026]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements [Selected]

Press release 17 July 2026

UNICEF Executive Director Catherine Russell visits Nigeria, spotlighting children's potential as the country's greatest opportunity

ABUJA/NEW YORK, 17 July 2026, – UNICEF Executive Director Catherine Russell today completed a mission to Nigeria, underscoring the potential of the country's children and the need for sustained investment to protect recent gains amid growing global and regional economic pressures. With nearly 105 million children ...

Statement 15 July 2026

"In the DRC, containing Ebola requires stronger collective action and a faster response"

DAKAR, 15 July 2026 –, "I have just returned from a mission in Ituri province, in the east of the Democratic Republic of Congo, with a strengthened conviction: Ebola can be contained, provided that we act faster and more collectively. "The epidemic continues to spread. Five provinces are now affected: Ituri, North...

Press release 15 July 2026

Over 23 million additional children at risk of poverty as Middle East conflict drives global economic shock – UNICEF

NEW YORK, 16 July 2026, –, Up to 23.4 million additional children could fall into monetary poverty by the end of the year, as ongoing tensions in the Middle East and related shipping disruptions continue to have a damaging and potentially irreversible impact on children, according to a new analysis by UNICEF relea...

Press release 14 July 2026

Global childhood immunization coverage inches forward despite conflict and hesitancy – UNICEF, WHO

GENEVA/NEW YORK, 15 July 2026, –In 2025, 90 per cent of infants globally –or nearly 116 million– received at least one dose of a diphtheria, tetanus and pertussis (DTP) vaccine, and 85 per cent –or 110 million– completed the full three-dose series, according to the annual WHO-UNICEF Estimates of National Imm...

Press release 12 July 2026

UNICEF calls for urgent action as peak wasting season nears and child food and nutrition insecurity puts 3.7 million children in Afghanistan at heightened risk of malnutrition

KABUL, 12 July 2026, – A new <https://www.unicef.org/afghanistan/documents/too-little-too-late> UNICEF report released today highlights that child food and nutrition insecurity is one of the primary drivers putting 3.7 million children under the age of five in Afghanistan at increased risk of undernutrition, unde...

Unitaid [18 July 2026]

<https://unitaid.org/>

News releases

Unitaid and CHAI cut cost of AI screening software, unlocking affordable TB detection in communities without radiologists

17 July 2026

News releases

PATH and Unitaid partner with GiveWell to strengthen integrated HIV and syphilis testing for mothers, newborns, and their families

14 July 2026

News releases

Unitaid analysis reveals critical gaps in private sector malaria care

14 July 2026

Vaccine Equity Cooperative [nee Initiative] [18 July 2026]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified. [Last update Jun 30, 2023]

Vaccine Confidence Project [18 July 2026]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [18 July 2026]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

Vaccine Update Newsletter June/July 2026

Wellcome Trust [18 July 2026]

<https://wellcome.org/>

News. Opinion, Reports

No new digest announcements identified.

The Wistar Institute [to 18 July 2026]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

World Bank [to 18 July 2026]

<http://www.worldbank.org/en/news/all>

News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [18 July 2026]

<https://www.wfpha.org/>

Blog, Events

No new digest announcements identified.

World Medical Association [WMA] [to 06 Sep 025]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest announcements identified.

World Organisation for Animal Health [WOAH/OIE] [18 July 2026]

<https://www.oie.int/>

Latest News

No new digest announcements identified.

.....

.....

ARM [Alliance for Regenerative Medicine] [18 July 2026]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest announcements identified.

BIO [18 July 2026]

<https://www.bio.org/press-releases>

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [18 July 2026]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

EFPIA – European Federation of Pharmaceutical Industries and Associations

<https://www.efpia.eu/news-events/>

News & Events

Statements & press releases 14.07.26

[EFPIA response to UK Switzerland Free Trade Agreement](#)

Statements & press releases 13.07.26

[German Parliament passes Statutory Health Insurance Contribution Stabilization Act: EFPIA response](#)

ICBA – International Council of Biotechnology Associations [18 July 2026]

<https://internationalbiotech.org/>

News

No new digest announcements identified.

IFPMA [18 July 2026]

<https://ifpma.org/>

News & Resources

Statement 15 July 2026

Global biopharmaceutical CEOs response to reforms introduced in Germany

By IFPMA

In response to reforms adopted by the German government on 10 July, BCR Secretary General, and IFPMA Director General, Dr. David Reddy, said:

"The legislation passed by the German government undermines the value of medical innovation, global competitiveness and patient access to new medicines. Failing to reflect the value that medicines and vaccines bring, will negatively impact the availability of new medicines for patients and lead to reduced levels of investment in research and development.

The German Government must act to reverse the current direction which undermines Germany's position as a leading location for pharmaceutical innovation and investment."

International Alliance of Patients' Organizations – IAPO [18 July 2026]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [18 July 2026]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.

AstraZeneca

Press Releases - No new digest announcements identified.

Bavarian Nordic

Latest News

July 13, 2026

Bavarian Nordic's Chikungunya Vaccine Submitted for Regulatory Approval in Brazil

COPENHAGEN, Denmark, July 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that its partner, Eurofarma, has submitted a marketing authorization application to the Brazilian Health Regulatory Agency (Anvisa) for Bavarian Nordic's chikungunya vaccine, CHIKV VLP, for the prevention of disease caused by chikungunya virus in individuals 12 years of age and older...

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified.

Biological E

News - No new digest announcements identified.

BioNTech

Press Releases - No new digest announcements identified.

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry.

CIGB

Latest News - No new digest announcements identified.

CinnaGen – Iran

CinnaGen News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

CSL Seqirus

News Releases - No new digest announcements identified.

Curevac

News - Website now directs to BioNTech site

Dailchi Sankyo

Press Releases - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media - No new digest announcements identified.

EuBiologics, S Korea

News - No new digest announcements identified.

HIPRA

Press releases - Website under maintenance.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

Merck

News releases - No new digest announcements identified

Moderna

News and Blog Posts - No new digest announcements identified.

Nanogen

News - No new digest announcements identified.

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Samsung Biologics

Latest News - No new digest announcements identified

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute

News & Announcements

Thursday, July 16, 2026

[Gates Medical Research Institute and SII Reach Agreement for the Manufacture of M72/AS01E Tuberculosis Vaccine Candidate, Pending Successful Phase 3 Outcomes](#)

CAMBRIDGE, MA / PUNE (July 16, 2026) - The Gates Medical Research Institute (Gates MRI) has reached a milestone agreement with the Serum Institute of India Private Limited (SII) to manufacture M72/AS01E, a novel tuberculosis (TB) vaccine candidate. Currently in a Phase 3 clinical trial, M72/AS01E has the potential to be the first new TB vaccine to be introduced in more than a century – a potential breakthrough against a disease that remains the world's leading infectious cause of death and disproportionately impacts low- and middle-income countries...

Sinopharm/WIBPBIBP

News - No new digest announcements identified.

Sinovac

Press Releases - No new digest announcements identified.

SK Biosciences

Press Releases - No new digest announcements identified.

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases - No new digest announcements identified.

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
Website [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)
:: [WHO](#)
:: [Organization Announcements](#)
:: [Journal Watch](#)
:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 17 2026 Issue 2

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 12: E823-875 December 2025

<https://journalofethics.ama-assn.org/issue/aging-bad-you>

Aging Is Bad for You?

At some point along life's trajectory, growing becomes aging. Gerotherapeutics—biologically-based approaches to health that target processes of aging—seem poised to respond. This theme issue investigates ethical valences of what gerotherapeutics suggest about our socially, culturally, and historically entrenched patterns of pathologizing and medicalizing aging. Advancement in our understanding of physiological mechanisms of aging has prompted some to reconceive lifespans as health spans. Geroscience also suggests the need to critically evaluate whether and to what extent we should think of anti-aging ventures as legitimate enterprises of health care. Normative roles played by aging in our personal and relational narratives, in our expectations about how duration and quality of life confer value to life, and in how life extension promotes or undermines our notions of wisdom and a good life are all at stake.

American Journal of Human Genetics

Jul 02, 2026 Volume 113 Issue 7 p1365-1582

<https://www.cell.com/ajhg/current>

This month in The Journal

Paul W. Hook, Alyson B. Barnes

Nondisjunction, the failure of chromosomes to separate, results in aneuploidies, in which cells have an abnormal number of chromosomes. Centromeres play an essential role in segregation of homologous chromosomes and sister chromatids. It has been hypothesized that centromere size, sequence, allelic difference, and epigenetic features might influence nondisjunction and, therefore, aneuploidy risk. Until recently, however, it has been difficult to study the sequence of human centromeres due to limitations of short-read sequencing.

[Reviewed earlier]

American Journal of Infection Control

August 2026 Volume 54 Issue 8 p829-930

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

July 2026 Volume 71 Issue 1

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

July 2026 116(53)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 115 (2026): Issue 1 (Jul 2026)

<https://www.ajtmh.org/view/journals/tpmd/115/1/tpmd.115.issue-1.xml>

[Reviewed earlier]

Annals of Internal Medicine

June 2026 Volume 179, Issue 6

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 355 June 2026

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/355/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 18 July 2026)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 18 July 2026)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 18 July 2026)

[**Response to a vaccine-derived poliovirus type 1 event — Sichuan, China, 2024**](#)

Qing Yang, Jiajie Liu, Qi Qi

Research Open access 17 July 2026

[**Influenza vaccine effectiveness according to frailty status in adults aged \$\geq 50\$ years: a systematic review and meta-analysis**](#)

Henrique Pott, Shelly A. McNeil, Melissa K. Andrew

Systematic Review Open access 11 July 2026

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 18 July 2026)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 18 July 2026)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 18 July 2026)

[No new digest content identified]

BMC Public Health

<http://bmcpublikealth.biomedcentral.com/articles>

(Accessed 18 July 2026)

[**HPV knowledge and willingness to receive HPV vaccine among female secondary school students in Ebonyi State, Nigeria: a pre-post evaluation of an educational intervention**](#)

Chinenye Angela Ogbu, Elvis Anyaehiechukwu Okolie, Cosmas Nnadozie Ezejindu

Research Open access 14 July 2026

[**Cervical cancer screening and HPV vaccination among assigned female at birth transgender and gender-diverse individuals in South Korea: findings from the KITE cohort**](#)

Jung-won Yoon, Gaeun Kim, Hyein Chu

Research Open access 13 July 2026

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>
(Accessed 18 July 2026)
[No new digest content identified]

BMJ Evidence-Based Medicine

June 2026 - Volume 31 - 3
<https://ebm.bmj.com/content/31/2>
[Reviewed earlier]

BMJ Global Health

June 2026 - Volume 11 - 6
<https://gh.bmj.com/content/11/6>
[Reviewed earlier]

Bulletin of the Atomic Scientists

DIGITAL MAGAZINE - May 2026
<https://thebulletin.org/magazine/2026-05/>
[Reviewed earlier]

Bulletin of the World Health Organization

Volume 104, Number 7, July 2026, 441-524
<https://www.who.int/publications/journals/bulletin>
Articles

[An umbrella protocol for the clinical evaluation of diagnostics in infectious disease.](#)

Blandford E, Tunkel S, Coates E, Arevalo CR, Kolstoe SE, Edeghere O, Maleady-Crowe F, Chapman D, Lewis C, Kulasegaran-Shylini R, Vipond R, Williamson DA, Pebody R, Oliver I, Hopkins S, Hill S, Fowler T.

[Ebola at a critical juncture: preparedness must outpace transmission.](#)

Susanto H, Huda MH, Duong MC, Susilawati TN.

Cell

Jul 09, 2026 Volume 189 Issue 14 p4185-4518
<https://www.cell.com/cell/current>
Articles
[Reviewed earlier]

Cell and Gene Therapy Insights

February 2026 Issue, Volume 12 Issue 1
<https://www.insights.bio/cell-and-gene-therapy-insights/journal/283/volume-12-issue-1>
[Reviewed earlier]

Child Care, Health and Development

Volume 52, Issue 4 July 2026
<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 119, Issue 6 Pages: 1393-1673 June 2026

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

June 2026 Volume 48 Issue 6 p485-552

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 23 Issue 3, June 2026

<https://journals.sagepub.com/toc/CTJ/current>

Articles

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 18 July 2026]

[No new digest content identified]

Contemporary Clinical Trials

Volume 166 July 2026

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/166/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 9 Issue 3, June 2026

<https://journals.sagepub.com/toc/tcja/9/3>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 13, Issue 1 December 2025

<https://link.springer.com/journal/40142/volumes-and-issues/13-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 42, Issue 1, 2026

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

August 2026 - Volume 39 - Issue 4

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 18 July 2026]

[No new digest content identified]

Cytotherapy

September 2026 Volume 28 Issue 9

<https://www.isct-cytotherapy.org/current>

Reviews/Perspectives

[South America and Mexico's cell and gene therapy landscape: accelerating growth and persistent challenges](#)

Heloisa Brand, et al.

Published online: March 06, 2026 102142 Open Access

Developing World Bioethics

Volume 26, Issue 2 Pages: 81-130 June 2026

<https://onlinelibrary.wiley.com/toc/14718847/current>

Special Issue: Military Global Health Engagements

[Reviewed earlier]

Development in Practice

Volume 36, 2026 Issue 4

<https://www.tandfonline.com/toc/cdip20/36/4?nav=tocList>

[Reviewed earlier]

Development Policy Review

Volume 44, Issue 4 July 2026

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 20 - 2026

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 50, Issue 3 July 2026

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

eBioMedicine

Volume 128 June 2026

<https://www.sciencedirect.com/journal/ebiomedicine/vol/128/suppl/C>

[Reviewed earlier]

EMBO Reports

Volume 27, Issue 13 July 2026

<https://link.springer.com/journal/44319/volumes-and-issues/27-13>

Science & Society

[War is not a pandemic](#)

Shai Berlin, Mykhailo O Kompanets

Open access 15 June 2026 Pages: 3513 - 3516

Emerging Infectious Diseases

Volume 32, Number 6—June 2026

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 55 June 2026

<https://www.sciencedirect.com/journal/epidemics/vol/55/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 154 - 2026

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 48, Issue 3 Pages: 1-46 May–June 2026

<https://onlinelibrary.wiley.com/toc/25782363/current>

[Reviewed earlier]

Ethics & International Affairs

Volume 39 - Issue 4 - Winter 2025

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue> [

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 33 2025

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/33/suppl/Cc>

[Reviewed earlier]

The European Journal of Public Health

Volume 36, Issue 3, June 2026

<https://academic.oup.com/eurpub/issue/36/3>

[Reviewed earlier]

Expert Review of Vaccines

Volume 25, 2026 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

May/June 2026 Volume 105, Number 3

<https://www.foreignaffairs.com/issues/2026/105/3>

[Reviewed earlier]

Forum for Development Studies

Volume 53, 2026 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities

[New issue: No digest content identified]

Frontiers in Genetics

<https://www.frontiersin.org/journals/genetics>

[Accessed 18 July 2026]

Editorial Published on 16 Jul 2026

[Editorial: Omic technologies, integrative methods and translational approaches in brain health and disease](#)

Paolo Abondio, Francesco Bruno, Shaoyu Wang

Frontiers in Genome Editing

<https://www.frontiersin.org/journals/genome-editing>

[Accessed 18 July 2026]

Policy and Practice Reviews Accepted on 13 Jul 2026

[Navigating the human gene editing scene and proposing a new governance framework in Africa: From Knowledge to Policy to Action](#)

Abdallah Borham, et al.

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 18 July 2026]

[No new digest content identified]

Gene Therapy – Nature

Volume 33 Issue 3, May 2026

<https://www.nature.com/gt/volumes/33/issues/3>
[Reviewed earlier]

Genetics in Medicines

Volume 28, Issue 7 July 2026

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/28/issue/7>

Practice guidelines Complimentary access

[Points to consider for the reporting of variants of uncertain significance in germline genetic and genomic testing: A statement of the American College of Medical Genetics and Genomics \(ACMG\)](#)

Chloe Mighton, Aya Abu-El-Haija, Vimla Aggarwal, Yassmine M.N. Akkari, ... Heidi L. Rehm
Article 102583

Review article Open access

[Best practices in demographic data collection for equity, diversity, and inclusion in rare disease research: A systematic review](#)

Israa Sinan, Molly Johnston, Ashish Marwaha
Article 102592

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 18 July 2026]

[No new digest content identified]

Global Health Action

Volume 19, Issue 1 (2026)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

December 2025 | Volume 13 | Number 2

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 18 July 2026]

[No new digest content identified]

Global Public Health

Volume 21, Issue 1 (2026)

<http://www.tandfonline.com/toc/rqph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 18 July 2026]

Institutional quality and pandemic resilience: cross-country evidence on health and economic outcomes during COVID-19

Diego A. Diaz, Cristian Larroulet, Andres Marticorena

Research Open access 16 July 2026

Health and Human Rights

Volume 28, Issue 2, June 2026

<https://www.hhrjournal.org/volume-28-issue-1-june-2026/>

Special Section: Children's Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 21 - Issue 2 - April 2026

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 41, Issue 6, June 2026

<https://academic.oup.com/heapol/issue/41/6>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 18 July 2026]

[No new digest content identified]

Human Gene Therapy

Volume 37 Issue 13-14, July 2026

<https://journals.sagepub.com/toc/hgta/37/13-14>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

[Accessed 18 July 2026]

[No new digest content identified]

Immunity

Jun 09, 2026 Volume 59 Issue 6 p1473-1776

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 18 July 2026]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

Latest articles

[No new digest content identified]

International Health

Volume 18, Issue 4, July 2026

<https://academic.oup.com/inthealth/issue/18/4>

[Reviewed earlier]

International Human Rights Law Review

Volume 15 (2026): Issue 1 (Jun 2026)

<https://brill.com/view/journals/hrlr/hrlr-overview.xml>

[Reviewed earlier]

The International Journal of Children's Rights

Volume 34 (2026): Issue 2 (Jun 2026)

<https://brill.com/view/journals/chil/34/1/chil.34.issue-2.xml>

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 13 No. 6 (2026): June 2026

<https://www.ijcmph.com/index.php/ijcmph/issue/view/137>

Articles

[Reviewed earlier]

International Journal of Epidemiology

Volume 55, Issue 3, June 2026

<https://academic.oup.com/ije/issue/55/3>

Original Articles

[**Age-specific mortality patterns across influenza pandemics: evidence from all-cause mortality data across multiple populations**](#)

Lauren E Steele and others

[**Estimates of vaccine effectiveness against measles and mumps: 14 years follow-up of a large cohort in Wales, UK**](#)

Malorie Perry and others

Opinion

Overcoming research challenges in sub-Saharan Africa: insights from the PREECARDIA study

Ruben Turé and others

From siege to spillover: how Gaza's health crisis threatens global infection spread

Muna Abed Alah and Peter Valentine Coyle

International Journal of Human Rights in Healthcare

Volume 19, Issue 2 22 April 2026

<https://www.emerald.com/ijhrh/issue/19/2>

[New issue: No digest content identified]

JAMA

July 14, 2026, Vol 336, No. 2, Pages 89-176

<https://jamanetwork.com/journals/jama/currentissue>

Viewpoint

Resurgence of Tetanus—Why the Vaccine Remains Instrumental

Kathryn M. Edwards, MD; Mobeen H. Rathore, MD

JAMA. 2026;336(2):99-100. doi:10.1001/jama.2026.9347

This Viewpoint discusses the reasons why it is important for individuals to continue to receive the tetanus vaccine.

JAMA Health Forum

June 2026, Vol 7, No. 6

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

June 2026, Vol 180, No. 6, Pages 593-706

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JB1 Evidence Synthesis

June 2026 - Volume 24 - Issue 6

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

June 2026 Volume 78 Issue 6 p835-956

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 85 (2026)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 51, Issue 3 June 2026

<https://link.springer.com/journal/10900/volumes-and-issues/51-3>

[Reviewed earlier]

Journal of Development Economics

Volume 182 June 2026

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/181/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 21 Issue 3, July 2026

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

June 2026 - Volume 80 - 6

<https://jech.bmj.com/content/80/3>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 19, Issue 2 June 2026

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 22, Issue 1 (2026)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 37, Number 2, May 2026

<https://muse.jhu.edu/issue/56930>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 28, Issue 3 June 2026

<https://link.springer.com/journal/10903/volumes-and-issues/28-3>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 24, Issue 2 (2026)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 38, Issue 5 Pages: 773-931 July 2026

<https://onlinelibrary.wiley.com/toc/10991328/current>

[New issue; No digest content identified]

Journal of Law, Medicine & Ethics

Volume 54 - Issue 1 - Spring 2026

<https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/latest-issue>

[Reviewed earlier]

Journal of Medical Ethics

June 2026 - Volume 52 - 6

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 13, Issue 2 (2026)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 294 July 2026

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/294/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 19, 2026 Issue 1

<https://www.tandfonline.com/toc/jppp20/19/1?nav=tocList>

[Reviewed earlier]

Journal of Public Health Management & Practice

May/June 2026 - Volume 32 - Issue 3

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 47, Issue 2 June 2026

<https://link.springer.com/journal/41271/volumes-and-issues/47-2>

[Reviewed earlier]

Journal of the Royal Society – Interface

Volume 23, Issue 240 1 July 2026

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 33, Issue 5, July 2026

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

The Lancet

Jul 18, 2026 Volume 408 Number 10551 p187-292

<https://www.thelancet.com/journals/lancet/issue/current>

Review

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective

Anna K Blakney, Karina A Top, Benjamin J Cowling, Heidi J Larson, Robin J Shattock, Manish Sadarangani

Summary

mRNA vaccines represent a transformative advance in vaccinology, combining rapid development timelines, scalable manufacturing, and strong immunogenicity with a favourable safety profile. Global deployment of mRNA vaccines during the COVID-19 pandemic provided an unprecedented real-world evaluation of this platform, with billions of doses administered across diverse populations. In this Review, we critically examine the safety and efficacy of mRNA vaccines from mechanistic, preclinical, clinical, and public health perspectives.

We outline the biological basis of mRNA vaccines, including their transient cytoplasmic expression, lack of genomic integration, and rapid clearance, distinguishing them clearly from other gene therapies. We synthesise evidence on vaccine components, manufacturing quality controls, and regulatory standards that underpin safety, alongside data from randomised trials, post-authorisation surveillance, and active pharmacovigilance systems. We also review real-world effectiveness across age groups, pregnancy, and populations that are immunocompromised, along with the effects on transmission.

Last, we address public perception and vaccine confidence, and discuss implications for next-generation mRNA vaccines, including strategies to reduce reactogenicity, improve breadth and durability of immunity, enhance global access, and support sustainable public trust. Together, the accumulated evidence affirms mRNA vaccines as a safe, effective, and adaptable platform with enduring relevance for future infectious disease prevention and public health preparedness, and for the treatment of cancer and autoimmunity.

The Lancet Child & Adolescent Health

Jun 2026 Volume 10 Number 6 p393-468

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Jun 2026 Volume 8 Number 6

<https://www.thelancet.com/journals/lancet/issue/current>

Viewpoint

Co-intelligence: a proposal for human–artificial intelligence collaboration for large language models in medical research

Ariel Yuhan Ong, et al.

Summary

The emergence of large language models (LLMs) offers transformative potential for medical research. Current approaches often focus on LLMs as a replacement for researchers or as a supporting tool. In this Viewpoint, we discuss the concept of co-intelligence, leveraging the strengths of both humans and LLMs for complementary and synergistic collaboration to accelerate scientific advancement while mitigating limitations. We discuss the theoretical underpinnings of co-intelligence and advocate for its role in medical research. Through this Viewpoint, we also aim to highlight key considerations, discuss potential unintended consequences, and provide actionable insights for researchers and clinicians seeking to maximise the use of LLMs while maintaining the rigour and integrity of their work.

Lancet Global Health

Jun 2026 Volume 14 Number 6

<https://www.thelancet.com/journals/langlo/issue/current>

Articles

[Reviewed earlier]

Lancet Infectious Diseases

Jun 2026 Volume 26 Number 6 p549-650, e209-e267

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Jun 2026 Volume 11 Number 6 e349-e416

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Jun 2026 Volume 14 Number 6 p463-566, e33-e40

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 30, Issue 6 June 2026

https://link.springer.com/journal/10_995/volumes-and-issues/30-6

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 46 Issue 6, August 2026

<https://journals.sagepub.com/toc/MDM/current>

Editorial

Revaccination after an Adverse Event: A Patient Uses Bayesian Reasoning to Weigh COVID and Vaccine Risks

J. Hansen

Medical Law International

Volume 26 Issue 2, June 2026

<https://journals.sagepub.com/toc/MLI/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 104, Issue 2 Pages: 293-580 June 2026

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Molecular Therapy

Jul 01, 2026 Volume 34 Issue 7 p3709-4338

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

Nature

Volume 655 Issue 8123, 16 July 2026

<https://www.nature.com/nature/volumes/655/issues/8123>

Editorial 15 Jul 2026

[Why there needs to be a global debate on inequality](#)

Researchers have a responsibility to search for consensus on this crucial issue, both for future generations and the future of our planet.

World View 14 Jul 2026

[Africa's response to this Ebola outbreak shows how to shape global health](#)

Countries elsewhere must learn from the continent's example and combat disease outbreaks by working together, not by closing borders.

Nature Biotechnology

Volume 44 Issue 6, June 2026

<https://www.nature.com/nbt/volumes/44/issues/6>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 18 July 2026)

[Reviewed earlier]

Nature Genetics

Volume 58 Issue 6, June 2026

<https://www.nature.com/ng/volumes/58/issues/6>

[Reviewed earlier]

Nature Human Behaviour

Volume 10 Issue 6, June 2026

<https://www.nature.com/nathumbehav/volumes/10/issues/6>

[Reviewed earlier]

Nature Medicine

Volume 32 Issue 6, June 2026

<https://www.nature.com/nm/volumes/32/issues/6>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 25 Issue 6, June 2026

<https://www.nature.com/nrd/volumes/25/issues/6>

[Reviewed earlier]

Nature Reviews Genetics

Volume 27 Issue 6, June 2026

<https://www.nature.com/nrg/volumes/27/issues/6>

[Reviewed earlier]

Nature Reviews Immunology

Volume 26 Issue 6, June 2026

<https://www.nature.com/nri/volumes/26/issues/6>

[Reviewed earlier]

New England Journal of Medicine

Volume 395 No. 3 July 16, 2026

<https://www.nejm.org/toc/nejm/medical-journal>

Review Article

[Bundibugyo Virus Disease in 2026 — Clinical and Public Health Responses](#)

N.J. Sullivan

Summary

Bundibugyo virus is a relatively rare orthoebolavirus that has caused only two previously recognized disease outbreaks but remains capable of producing severe epidemic disease with substantial mortality. The 2026 outbreak of Bundibugyo virus disease in the Democratic Republic of Congo has highlighted persistent challenges in the detection of filovirus disease outbreaks, as well as in diagnosis, clinical management, and the public health response, particularly in resource-limited settings. As with other filovirus infections, effective control of the Bundibugyo virus disease outbreak depends on rapid identification of cases, laboratory confirmation of infection, isolation of cases, contact tracing, infection-prevention measures, protection of health care workers, and community engagement. Although no licensed vaccines or approved therapeutics specific to Bundibugyo virus disease are currently available, advances in supportive care have improved outcomes during recent filovirus disease outbreaks. Experimental evidence from studies involving nonhuman primates, serologic investigations with human samples, and monoclonal antibody research suggests that vaccines and therapeutics developed against Ebola virus may provide cross-protective activity against Bundibugyo virus. These observations support prototype-pathogen approaches to preparedness while underscoring the need for continued

development of pathogen-specific countermeasures. The current outbreak reinforces the principle that a successful response to filovirus disease requires integration of medical countermeasures, clinical care, surveillance, diagnostics, and coordinated multinational public health operations.

NEJM Evidence

Volume 5 No. 6 June 2026

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 18 July 2026]

[Reviewed earlier]

Pediatrics

Volume 158, Issue 1 July 2026

<https://publications.aap.org/pediatrics/issue/158/1>

[Reviewed earlier]

PharmacoEconomics

Volume 44, Issue 6 June 2026

<https://link.springer.com/journal/40273/volumes-and-issues/44-6>

Articles

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 18 July 2026)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 18 July 2026)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 18 July 2026)

[**Beyond benchmarking: Using WHO's NPHA capability framework as a driver of institutional reform**](#)

Geoffrey Namara, Catherine Smallwood, Alexandra Zuber, Sara Hersey, Chikwe Ihekweazu
Opinion | published 17 Jul 2026 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0006882>

[Estimating the basic reproduction number of measles in low-and middle-income settings using 172 seroprevalence studies: A modelling approach](#)

Han Fu, Alyssa N. Sbarra, Timothy Russell, Kaja Abbas, Megan Auzenberg, Mark Jit

Research Article | published 17 Jul 2026 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0006731>

[Progress towards measles and rubella elimination in Eswatini by 2024](#)

Xolisile Dlamini, Tholokwakhe Simelane, Susan Kamalizeni, Lonkululeko Khumalo, Angel Dlamini, Kassahun Mitiku, Balcha Masresha

Research Article | published 16 Jul 2026 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0006860>

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 18 July 2026)

[Re-emergence of vaccine-preventable diseases in the post-elimination era](#)

Chirag K. Kumar, Nathan C. Lo

Perspective | published 16 Jul 2026 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1005175>

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 18 July 2026)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 18 July 2026]

[No new digest content identified]

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 18 July 2026]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

July 14, 2026 vol. 123 no. 28

<https://www.pnas.org/toc/pnas/123/28>

Science in Service: Behavioral Research Applications across Federal Agencies

Introduction July 6, 2026

[Science in service: Behavioral research applications across federal agencies](#)

Alycia Chin and Baruch Fischhoff

Perspective July 6, 2026

Applied behavioral and decision sciences in support of US FDA's drug regulatory mission

The US Food and Drug Administration (FDA) makes and communicates decisions that directly affect the health choices and well-being of the US public. Behavioral and decision scientists have long supported FDA's pharmaceutical (medical drug) regulatory and ...

Sara L. Eggers, Tamar Krishnamurti and Baruch Fischhoff

PNAS Nexus

Volume 5, Issue 5, May 2026

<https://academic.oup.com/pnasnexus/issue/5/5>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 41 - Issue 1 - 2026

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 207 June 2026

<https://www.sciencedirect.com/journal/preventive-medicine/vol/207/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

Volume 293, Issue 2072 June 2026

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

Public Health

Volume 255 June 2026

<https://www.sciencedirect.com/journal/public-health/vol/255/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 18, Issue 2, July 2025

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2026, Vol. 29, No. 1

<https://karger.com/phg/issue/29/1>

[Reviewed earlier]

Public Health Reports

Volume 141 Issue 3, May/June 2026

<https://journals.sagepub.com/toc/phrg/141/3>

[Reviewed earlier]

Qualitative Health Research

Volume 36 Issue 7, June 2026

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 22 Issue 3, July 2026

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 18 July 2026]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

[No new digest content identified]

Risk Analysis

Volume 46, Issue 7 July 2026

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 18 July 2026]

[No new digest content identified]

Royal Society Open Science

Volume 13, Issue 7 1 July 2026

<https://royalsocietypublishing.org/toc/rsos/current>

[New issue; No digest content identified]

Science

Volume 393| Issue 6808| 16 Jul 2026

<https://www.science.org/toc/science/current>

Editorial

[AI in scientific publishing: Slower, worse, and more expensive](#)

BY H. Holden Thorp 16 Jul 2026

Science and Engineering Ethics

Volume 32, Issue 3 June 2026

<https://link.springer.com/journal/11948/volumes-and-issues/32-3>

[Reviewed earlier]

Science Translational Medicine

Volume 18| Issue 858| 15 Jul 2026

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 18 July 2026]

[No new digest content identified]

Social Science & Medicine

Volume 398 June 2026

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/398/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 18 July 2026]

[**Safety, immunogenicity, efficacy, and effectiveness of mpox vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis**](#)

Jamile Ballivian, Agustín Ciapponi, Pierre M. Buekens

Protocol Open access 18 July 2026

Theoretical Medicine and Bioethics

Volume 47, Issue 4 August 2026

<https://link.springer.com/journal/11017/volumes-and-issues/47-4>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 71 May–June 2026

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/71/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 31, Issue 6 Pages: 657-765 June 2026

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 87 18 July 2026

<https://www.sciencedirect.com/journal/vaccine/vol/87/suppl/C>

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 18 July 2026]

Article

Development and Validation of an Extended Adult Vaccine Hesitancy Scale in Greek-Speaking Populations

Andria Hadjickou, et al.

Vaccines 2026, 14(7), 628; <https://doi.org/10.3390/vaccines14070628> (registering DOI)

16 July 2026

Background: Vaccine hesitancy (VH) is a complex global public health threat requiring validated tools for its assessment globally. This study aimed to evaluate an extended adult Vaccine Hesitancy Scale (aVHS) among Greek-speaking adults. Methods: Thi...

Review

Beyond PrEP: The Imperative for an HIV Vaccine to End the Epidemic in Africa

Nicaise Ndembu, et al and Jerome H. Kim

Vaccines 2026, 14(7), 627; <https://doi.org/10.3390/vaccines14070627> (registering DOI)

16 July 2026

The era of highly effective pre-exposure prophylaxis (PrEP) has transformed HIV prevention, yet global HIV incidence remains unacceptably high, particularly in sub-Saharan Africa. While antiretroviral-based prevention is critical, persistent structur...

Review

Maternal Immunization Against Respiratory Syncytial Virus: An Integrative Review of Efficacy, Safety, and Implementation

Isadora Rodrigues Almeida, et al.

Vaccines 2026, 14(7), 624; <https://doi.org/10.3390/vaccines14070624>

15 July 2026

Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infection in young infants and accounts for substantial morbidity, hospitalization, and mortality worldwide, with the highest burden concentrated in the first mont...

Review

From Vaccine Skepticism to Institutional Distrust: The Post-Pandemic Shift

Francesco De Maria, et al.

Vaccines 2026, 14(7), 622; <https://doi.org/10.3390/vaccines14070622>

15 July 2026

Background: Vaccine hesitancy has traditionally been understood as a multifactorial phenomenon shaped by individual beliefs, risk perceptions, and access barriers. However, the COVID-19 pandemic has fundamentally transformed the relationship between..

Value in Health

June 2026 Volume 29 Issue 6 p921-1140

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Medical Journal – Official Journal of The World Medical Association

Nr. 4, December 2025, vol. 71

<https://www.wma.net/publications/world-medical-journal/>

[Reviewed earlier]

World Development

Volume 205 September 2026

<https://www.sciencedirect.com/journal/world-development/vol/205/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

Pre-Print Servers

arXiv

<https://arxiv.org/>

[Accessed 18 July 2026]

[*Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Computational Engineering, Finance, and Science; General Literature; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics*]

[arXiv:2607.11306](#) (cross-list from math.OC) [[pdf](#), [html](#), [other](#)]

[Optimal Control of Pandemic Dynamics via Model Predictive Control: A Health-Economic Trade-off Analysis](#)

[Lokman Rachid Melhani](#), [Lars Grune](#), [Antonino Sferlazza](#), [Dominique Persano Adorno](#), [Filippo D'Ippolito](#), [Alberto Firenze](#)

Comments: 17 pages, 4 figures. Companion papers: [arXiv:2606.07413](#) (model calibration and identification) and [arXiv:2606.16305](#) (EKF state estimation)

Subjects: Optimization and Control (math.OC); Systems and Control (eess.SY); Populations and Evolution (q-bio.PE)

[arXiv:2607.13914](#) (cross-list from eess.SY) [[pdf](#), [other](#)]

[Epidemic Informatics and Control: A Holistic Approach from System Informatics to Epidemic Response and Risk Management in Public Health](#)

[Hui Yang](#), [Siqi Zhang](#), [Runsang Liu](#), [Alexander Krall](#), [Yidan Wang](#), [Marta Ventura](#), [Chris Deflitch](#)
Journal-ref: AI and Analytics for Public Health (Springer, 2022)

<https://www.biorxiv.org/content/early/recent>

[Accessed 18 July 2026]

[Filters: *Bioengineering, Evolutionary Biology, Genetics, Genomics, Neuroscience, Synthetic Biology*]
Website not fully responding at inquiry.

medRxiv

<https://www.medrxiv.org/content/early/recent>

[Accessed 18 July 2026]

[Filter: *All articles*]

Website not fully responding at inquiry.

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 18 July 2026]

[Filter: *All articles*]

No new digest content identified.

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Filter: *OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints*]

No new digest content identified.

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 18 July 2026]

No new digest content identified.

*

*

*

*

Think Tanks

Brookings [to 18 July 2026]

<http://www.brookings.edu/>

Research, Events

No new digest content identified.

Center for Global Development [18 July 2026]

<https://www.cgdev.org/>

All Research

BRIEF

[An IDA Health Window: The Future of Global Health Financing](#)

Pete Baker

July 15, 2026

Summary

The global health architecture is facing a crisis of both financing and legitimacy. Gavi, the Vaccine Alliance and The Global Fund to Fight AIDS, Tuberculosis and Malaria have had their budgets cut by

over 20 percent, donors are urgently calling for reform, and low- and middle-income nations are demanding greater sovereignty over their health systems. Current reform processes have shied away from a precise prescription for a new financing mechanism. Without this, there can be no progress. An International Development Association (IDA) Health Window would resolve the challenges of the current architecture. This brief outlines its mission, policy objectives, and key design characteristics. It builds off a forthcoming working paper which reviews the World Bank's role in health financing...

Chatham House [to 18 July 2026]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [18 July 2026]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 18 July 2026]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

IS Global [to 18 July 2026]

<https://www.isglobal.org/en/>

Newsroom

No new digest content identified.

McKinsey Global Institute [to 18 July 2026]

<https://www.mckinsey.com/mgi/overview>

Featured Research

No new digest content identified.

ODI [Overseas Development Institute] [to 18 July 2026]

<https://odi.org/en/publications/>

Publications

No new digest content identified.

Pew Research Center [to 18 July 2026]

<https://www.pewresearch.org/>

Latest Publications

No new digest content identified.

Rand [to 18 July 2026]

<https://www.rand.org/pubs.html>

No new digest content identified.

Urban Institute [to 18 July 2026]

<https://www.urban.org/research>

New Research Publications - Selected

Brief July 8, 2026

Coverage Gains Plateaued for New Mothers as Pandemic Protections Ended

National and State Patterns, 2019–2024

Jennifer M. Haley, Vincent Pancini, Genevieve M. Kenney

World Economic Forum [to 18 July 2026]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

.....

.....

Public Consultations/Calls for Inputs/Calls for Papers

WMA - Declaration of Taipei Revision Launched [Ongoing]

...The Declaration of Taipei tries to achieve a balance between the rights of individuals giving their tissue or data for research and other purposes based on confidentiality and privacy rules while at the same time recognising that health data has become a very powerful tool for increasing knowledge.

In analysing the scenarios that already exist for the use (and misuse) of health data and biobanks, we came to the conclusion that the major risk scenarios may not result from science, but from the commercial, administrative or political use of such data. Limiting our guidelines to research only would have left us blind to the imminent risk of abuse from outside the field of medicine: commercialization, cost-cutting and potential political abuse.

Therefore, in contrast to the Declaration of Helsinki, this policy aims to address any use of health databases and biobanks excluding individual treatment and is not restricted to research. As physicians are the primary custodians of confidential health information, they feel an obligation towards their patients and other persons who entrust them with their data and specimens...

In April 2025, the WMA appointed a workgroup to initiate the revision process of this document. To encourage as much global participation in the revision process as possible, the WMA is collaborating with its members to host a series of regional meetings...

*

*

*

*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

*

*

*

*

*

*

*

*

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2026. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*